Rare disease biotech Aldeyra Therapeutics cuts proposed IPO deal size by 47%

By
A A A

Aldeyra Therapeutics, a clinical-stage biotech developing treatments for rare skin and eye diseases, lowered the proposed number of shares it is offering on its upcoming IPO on Friday. The Burlington, MA-based company now plans to raise $13 million by offering 1.2 million shares at a price range of $10 to $12. The company had originally filed to offer 2.0 million shares at the same range, before increasing it to 2.3 million shares last month. At the midpoint of the range, Aldeyra Therapeutics will raise 47% less in proceeds than previously anticipated.

Aldeyra Therapeutics, which was founded in 2004, plans to list on the NASDAQ under the symbol ALDX. It initially filed confidentially on December 4, 2013. Aegis Capital is the sole bookrunner on the deal. It is expected to price during the week of April 28, 2014.




The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.




This article appears in: News Headlines , IPOs

Referenced Stocks: ALDX

Renaissance Capital

Renaissance Capital

More from Renaissance Capital:

Related Videos

3 Great Stay-at-Home Jobs
3 Great Stay-at-Home Jobs           

Stocks

Referenced

100%

Most Active by Volume

121,542,429
  • $114.64 ▼ 3.21%
75,240,655
  • $40.31 ▲ 2.02%
71,068,407
  • $3.49 ▲ 4.49%
68,252,066
  • $17.80 ▲ 0.17%
36,462,005
  • $37.10 ▲ 11.92%
33,292,485
  • $21.75 ▲ 9.57%
32,729,543
  • $5.25 ▲ 1.94%
32,548,015
  • $47.54 ▲ 1.56%
As of 8/4/2015, 04:15 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com